Plain-English translation of NCT07236203 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing cell therapy — a personalized cancer treatment that uses your own immune cells to fight lymphoma that has returned or stopped responding to other treatments. Researchers want to understand why this medication works well for some patients but not others, by carefully tracking changes in your blood cells, immune system, and tumor during treatment.
Many patients with relapsed or refractory large B-cell lymphoma have limited options after standard treatments fail. By identifying which patients benefit most from this medication and understanding the biological reasons why, doctors hope to better predict treatment success and improve care for future patients.
You likely qualify if…
You likely don't qualify if…
You will receive a standardized 90-day course of cell therapy at the study center. During this time, researchers will monitor your response through blood tests, imaging, and other evaluations to track how your immune cells and tumor change. After treatment ends, if you respond well, you will enter long-term follow-up; if the treatment is not working, your doctor may recommend other options.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Enrollment target
~80 participants
Started
February 2024
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chuanxu Liu, M.D
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.